DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Breast cancer
Disease landscape and forecast

Rapidly evolving breast cancer space presents new market dynamics for drug developers
The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, HER2-targeting drugs in development are forecast to enter the market, while sales of current HER2-targeting agents will be impacted as a result of competition, label expansions, biosimilar entries, and new trials leading to changes in treatment guidelines.

What does the future hold for the breast cancer market?

Download the key insights to understand:

  • Current market dynamics
  • Market constraints
  • Current treatment dynamics
  • Unmet needs
  • Emerging pipeline drugs
Key insights – Breast cancer
Key questions answered in this report
  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as Tecentriq, Piqray, Enhertu, Tukysa, and Trodelvy on the various subpopulations of breast cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

If you’d like to see these insights for other markets, visit our report store to see our full range

Note – if your company has a DRG subscription you may be able to access this report by logging in, click here.